TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34255078
Drug: Phytoglycogen (PHY)
Normalized name: SUNSCREEN 30-50/PHY BLOCK/PABA-F LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoglycogen (PHY) at 2 g·min-1
Study: 34255140
Drug: Anti-inflammatory treatment
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory treatment initiated or increased
Study: 34255140
Drug: Treatment increased
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment increased
Study: 34255140
Drug: Anti-inflammatory therapy
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory therapy increased
Study: 34255535
Drug: BEMPEG 0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEMPEG 0.006 mg/kg plus NIVO 360 mg once every 3 weeks for ≤ 2 years
Study: 34255555
Drug: Food Supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food Supplement with Antioxidative Santa Herba Extract
Study: 34255727
Drug: VoiceAdapt mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VoiceAdapt mobile therapy app, used for 5 weeks of training.
Study: 34256279
Drug: Alisertib 40
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 40 mg BID on D1-3 per week plus nab-paclitaxel 100 mg/m²
Study: 34256732
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer patients receiving immunotherapy
Study: 34256967
Drug: Guideline recommendations
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline recommendations for first- to nth-line treatment of target mental health symptoms.
Study: 34256967
Drug: Approach to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approach to prescribing guidelines that incorporates real-world availability of treatments.
Study: 34259164
Drug: Web-based psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based psychotherapy plus treatment as usual (8 weeks)
Study: 34259164
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual exclusively
Study: 34259664
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (gas flow 0; 30-60 L/min)
Study: 34260435
Drug: Bilateral Cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral Cochlear Implants (BiCI)
Study: 34261508
Drug: E-MOTIVE bundle
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-MOTIVE bundle (1) Early PPH detection using a calibrated drape, (2) uterine Massage, (3) Oxytocic drugs, (4) Tranexamic acid, (5) Intra Venous fluids, (6) genital tract Examination and escalation when necessary.
Study: 34261794
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of RAR-related orphan receptor-positive LTi cells
Study: 34262403
Drug: Dydrogesterone 10
Normalized name: dydrogesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone 10 mg twice daily orally for 21 days (day 5-25 of each menstrual cycle) for 4 cycles
Study: 34262514
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT)-based preventive group intervention: EMOTION
Study: 34263020
Drug: PR-T 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-T 0.2 mg/kg/d (Arm 1)
Study: 34263020
Drug: PR-T 0.15-0.175
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-T 0.15-0.175 mg/kg/d plus basiliximab (Arm 2)
Study: 34263020
Drug: PR-T 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-T 0.2 mg/kg/d delayed until day 5 posttransplant plus basiliximab (Arm 3)
Study: 34263213
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (n=30), applied three times a week for the first 2 weeks
Study: 34263665
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous treatments)
Study: 34263738
Drug: Granulocyte CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granulocyte CSF (G-CSF), S100A8, IL-6
Study: 34264412
Drug: LY3076226 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3076226 at doses ranging from 0.2-5.0 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle.
Study: 34264732
Drug: Integrated cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cannabis and anxiety reduction treatment (ICART)
Study: 34265048
Drug: 9-valent HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent HPV (9vHPV) vaccine types
Study: 34265285
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brush cytology, MI_H, MI_N, and CA19-9
Study: 34265394
Drug: High-field MR-Linac
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-field MR-Linac treatment
Study: 34265433
Drug: Ensartinib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib at a dose of 225 mg once daily
Study: 34268426
Drug: Adjunctive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatments including types of oxygen support, ventilation, rescue therapies for hypoxemia, other adjunctive and supportive treatments, experimental therapies
Study: 34268623
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 ng/mL
Study: 34268623
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 ng/mL
Study: 34268623
Drug: Dexmedetomidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.5 ng/mL
Study: 34268711
Drug: IMC-001 (PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMC-001 (PD-L1 blocker) administered intravenously every 2 weeks at doses ranging from 2 to 20 mg/kg
Study: 34269152
Drug: Acalabrutinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib and Vistusertib combination therapy
Study: 34269698
Drug: Liquid chromatography-tandem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid chromatography-tandem mass spectrometry method for monitoring medication adherence
Study: 34269927
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab (IV-TCZ) 4 mg/kg
Study: 34270347
Drug: Continuous Glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Glucose Monitors and Insulin Pumps
Study: 38861398
Drug: Subcutaneous implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
Study: 34271312
Drug: IDH1-vac, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDH1-vac, a long IDH1R132H peptide vaccine
Study: 34272204
Drug: Palliative systemic
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative systemic treatment (usual care arm of GAP 70+ Trial)
Study: 34272204
Drug: Receipt of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of ≥second line of chemotherapy
Study: 34272724
Drug: Treatment withdrawal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment withdrawal after 180 days
Study: 34273485
Drug: Biologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic treatment
Study: 34273485
Drug: Maintenance systemic
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance systemic corticosteroids or uncontrolled by high-dosage inhaled corticosteroids
Study: 34273526
Drug: Transplant ePROM
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant ePROM (TXP) administered via mobile application
Study: 34273904
Drug: Secukinumab treatment
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab treatment for 52 weeks
Study: 34274393
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with sequential S-1
Study: 34274536
Drug: CD5-targeting fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5-targeting fully human heavy-chain variable (FHV) CAR-T therapy
Study: 34274536
Drug: Standard CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CAR-T therapy (implied control)
Study: 34275061
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose proton pump inhibitor (PPI) therapy for 4 weeks
Study: 34275336
Drug: Measurements of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurements of serum drug concentrations
Study: 34275403
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin 1.8 mg/kg by intravenous infusion on Day 1 of 3-week cycles (maximum 16 cycles)
Study: 34275469
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of breathing rate with Fourier coefficients, signal amplitude, and/or ARIMA coefficients
Study: 34276537
Drug: Dopamine Receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine Receptor D1
Study: 34277393
Drug: Neoadjuvant Endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Endocrine Therapy (NET) with gonadotropin-releasing hormone agonist and tamoxifen
Study: 34277393
Drug: Neoadjuvant Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Chemotherapy (NCT) with adriamycin plus cyclophosphamide followed by taxane
Study: 34277393
Drug: Neoadjuvant Endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Endocrine Therapy (NET)
Study: 34277437
Drug: Hormone measurements
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone measurements post HSCT (FSH and AMH)
Study: 34278053
Drug: Stereotactic radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiation therapy (30 Gy in 5 fractions) for patients with 24 and 30 lesions.
Study: 34278053
Drug: Stereotactic radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiation therapy (12 Gy in 2 fractions) for the patient with 50 targets.
Study: 34278053
Drug: Stereotactic radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiation therapy treatment plans using volumetric modulated arc therapy.
Study: 34278100
Drug: Dyed sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dyed sucralfate gel
Study: 34278169
Drug: selonsertib, firsocostat,
Approvals — FDA: no, EMA: no, PMDA: no
Description: selonsertib, firsocostat, or cilofexor, alone or in two-drug combinations
Study: 34280258
Drug: Ibrutinib (BTK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (BTK inhibitor)
Study: 34280258
Drug: Asparaginase (ASNase)
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asparaginase (ASNase) therapy
Study: 34280257
Drug: WT1-TCB antibody
Normalized name: TCB-008
DrugBank: TCB-008 (DB18352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT1-TCB antibody
Study: 34281363
Drug: Ticagrelor Monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor Monotherapy
Study: 36535779
Drug: Ticagrelor with
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor with Aspirin
Study: 34281614
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (MDA) for soil-transmitted helminths (STH)
Study: 34281912
Drug: GSK2636771 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2636771 (200 mg) plus enzalutamide (160 mg)
Study: 34281912
Drug: GSK2636771 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2636771 (300 mg) plus enzalutamide (160 mg)
Study: 34281912
Drug: GSK2636771 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2636771 (400 mg) plus enzalutamide (160 mg)
Study: 34282079
Drug: Outpatient motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient motivational enhancement therapy (4 sessions)
Study: 34282079
Drug: Outpatient motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient motivational enhancement therapy followed by community reinforcement approach for seniors (8 sessions)
Study: 34282496
Drug: Deceased donor
Normalized name: Dexased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deceased donor liver-derived natural killer (NK) cell infusion
Study: 34283023
Drug: Tablet intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet intervention containing IPV questions and a film to promote safety behaviors
Study: 34283629
Drug: Continuous 5-aza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 5-aza treatment
Study: 34284523
Drug: NF-κB decoy
Normalized name: NF-kappaB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NF-κB decoy injection into degenerated IVDs
Study: 34284523
Drug: NF-κB decoy
Normalized name: NF-kappaB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NF-κB decoy injection
Study: 34284599
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) performed in 175 patients (51.6%); mechanical thrombectomy in 139 patients.
Study: 34284599
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) group.
Study: 34285010
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application for data collection including personal profile, monthly event tracker, and patient-reported outcomes instruments.
Study: 34285010
Drug: Myasthenia Gravis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myasthenia Gravis Activities of Daily Living
Study: 34285598
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily (days 1-5) + Trazpiroben 25 mg post itraconazole on day 4
Study: 34286103
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose rifampicin and adjunctive linezolid, with or without aspirin
Study: 34286354
Drug: Best possible
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best possible medication history (BPMH) by hospital pharmacist at inclusion and therapeutic drug monitoring
Study: 34286454
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.3 U/kg
Study: 34286454
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.2 U/kg
Study: 34286459
Drug: VP-102 topical
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP-102 topical application once every 14 days (Cohort 1)
Study: 34286459
Drug: VP-102 topical
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP-102 topical application once every 21 days in conjunction with paring (Cohort 2)
Study: 34286886
Drug: Pharmacy administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacy administration and dispensing of methadone for MMT (5-160 mg/day for 3 months)
Study: 34286886
Drug: Pharmacy administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacy administration and dispensing of methadone for MMT
Study: 34287023
Drug: Sertraline; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline; specific dosage and duration not available
Study: 34287217
Drug: Community-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based screening using an oral fluid-based rapid test (OFT)
Study: 34287262
Drug: Changing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changing the time of day for taking endocrine therapy (tamoxifen and/or aromatase inhibitors)
Study: 34287942
Drug: Lanadelumab 300
Normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 300 mg q2wks
Study: 34288026
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of post-transplant cyclophosphamide
Study: 34288271
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (levodopa)
Study: 34288547
Drug: Lorlatinib oral
Normalized name: lorlatinib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib oral solution
Study: 34289017
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg/d) and ulocuplumab (cycles 1 to 6, 4 weeks each)
Study: 34289656
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 (single dose) and oral prednisone (for at least 5 days) prior to chemoimmunotherapy
Study: 34289656
Drug: Rituximab/prednisone prephase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab/prednisone prephase treatment
Study: 34289656
Drug: Prephase treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prephase treatment
Study: 34291703
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide (CO2) laser treatment, 3 sessions over 20 weeks
Study: 34291703
Drug: Histological analysis
Normalized name: Entamoeba histolytica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histological analysis after CO2 laser treatment
Study: 34291703
Drug: Immunohistochemical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical analysis after CO2 laser treatment
Study: 34291813
Drug: Systemic corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant
Study: 34292174
Drug: Selective RET-inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective RET-inhibitors (selpercatinib and pralsetinib)
Study: 34292174
Drug: Investigation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigation of immune-based therapy
Study: 34292214
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of CoronaVac vaccine
Study: 34292516
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation (0.03 mg/kg)
Study: 34292537
Drug: Ba-Duan-Jin (BDJ)
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ba-Duan-Jin (BDJ) exercise and placebo capsule
Study: 34292537
Drug: Pregabalin capsule
Normalized name: Pregabalin Capsules
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin capsule and wellness education with guided muscle-relaxation exercises
Study: 34293119
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma with high neutralizing antibody titers
Study: 34293201
Drug: Intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-modulated radiation therapy with concurrent doxorubicin (CC-IMRT)
Study: 34293201
Drug: Intensity-modulated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity-modulated radiation therapy alone (IMRT)
Study: 34293527
Drug: Single-dose L-theanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose L-theanine
Study: 34295813
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy with intensity-modulated radiation therapy (IMRT) at a total dose of 40 Gy in 20 fractions.
Study: 34296417
Drug: Moxidectin 8
Normalized name: Advantage Multi for Cats (imidacloprid 80 MG / moxidectin 8 MG) per 0.8 ML Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin 8 mg fixed-dose
Study: 34296417
Drug: Moxidectin weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin weight-based dosing
Study: 34296674
Drug: Non-pharmaceutical interventions
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical interventions (NPI)
Study: 34297046
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m2) administered IV once daily on days 1 to 7 of a 28-day cycle
Study: 34297259
Drug: Online training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online training system with a 32-exercise training course providing online instruction (about 15 min/week) in 13 core family therapy techniques.